{"product_id":"envb-ansoff-analysis","title":"(ENVB) Enveric Biosciences, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Enveric Biosciences, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help you evaluate strategic priorities and investment implications; this page includes a real preview\/sample of the analysis so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVM-101 cancer distress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc.'s EVM-101 targets cancer-related distress, so a market penetration move would push deeper into the same oncology supportive-care niche rather than seek a new one. With more than 18 million cancer survivors in the U.S., the addressable care base is already large, so the goal is higher use inside existing cancer centers, not category expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVM-201 cancer distress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVM-201’s cancer-related distress angle fits a market penetration move: Enveric Biosciences can push deeper into oncology supportive care without changing its core focus. With the American Cancer Society estimating about 2.0 million new U.S. cancer cases in 2025, even a narrow distress-relief use case reaches a large, recurring need. That keeps the company selling into the same clinical problem, which can lower commercialization risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEV101 chemo adjunct\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEV101 is a cannabinoid-based chemo adjunct, so a penetration push means deeper use in current oncology workflows, not a new care lane. That fits existing cancer-care channels, where the world saw about 20 million new cancer cases and 9.7 million deaths in 2022. Enveric Biosciences reported no product revenue in its latest annual filing, so adoption matters more than channel expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCannabinoid oncology focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc. is aimed at cannabinoid-based cancer care, so market penetration means winning more share in that same niche, not expanding into a new one. The cleanest path is a tightly aligned pipeline that targets oncology pain, nausea, and treatment-side-effect use cases with one clear message. Global cancer burden remains huge, with about 20 million new cases a year, so even small share gains can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on one oncology use case.\u003c\/li\u003e\n\u003cli\u003eBuild share inside the same niche.\u003c\/li\u003e\n\u003cli\u003eUse a tightly aligned pipeline.\u003c\/li\u003e\n\u003cli\u003eTarget high-volume cancer care needs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc. keeps Market Penetration narrow by concentrating its pipeline on oncology-related and cannabinoid-based assets, so every candidate targets the same defined niche. That focus can sharpen brand recall, KOL outreach, and investor messaging, especially while the Company remains pre-revenue in its latest public filings. One market, multiple shots.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame core segment across programs\u003c\/li\u003e\n\u003cli\u003eLower scatter in commercial focus\u003c\/li\u003e\n\u003cli\u003eBetter use of limited capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnveric Targets Cancer-Care Penetration Amid Zero Product Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc. Market Penetration means pushing EVM-101 and related oncology-supportive care assets deeper into the same cancer-care niche, not entering a new market. That fits a large base of about 18 million U.S. cancer survivors and roughly 2.0 million new U.S. cancer cases in 2025, but the Company still had no product revenue in its latest filing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cancer survivors\u003c\/td\u003e\n\u003ctd\u003e18 million+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. new cancer cases, 2025\u003c\/td\u003e\n\u003ctd\u003eAbout 2.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003eNone reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Enveric Biosciences, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Enveric Biosciences Ansoff Matrix snapshot to simplify growth strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, clinical, and investor sources to validate Enveric’s growth-path assumptions and speed due diligence for Ansoff Matrix analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVM-101 palliative care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVM-101 fits market development: the same asset can move from oncology clinics into palliative care, widening use without changing the product. WHO says cancer caused about 10 million deaths in 2022, and palliative care needs are rising fast as patients live longer with distress, pain, and anxiety.\u003c\/p\u003e\n\u003cp\u003eThis matters because palliative care spans hospital, hospice, and home-based settings, so the addressable pool grows beyond oncology centers. If Enveric Biosciences, Inc. can support cancer-related distress in these settings, EVM-101 could reach more patients with the same core profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVM-201 hospice support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVM-201 could extend from cancer care into hospice and supportive care without changing the asset, which fits Ansoff’s market development move. U.S. hospice use is large: Medicare covered about 1.7 million hospice beneficiaries in 2023, and hospice care accounted for roughly $27 billion in spending. That gives Enveric Biosciences, Inc. a broader end-of-life market to reach with the same product concept.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEV101 infusion centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEV101 could move into infusion-center oncology workflows, taking the same asset into a new treatment-delivery market and fitting its chemotherapy-adjunct design. The U.S. is expected to see 2.0 million new cancer cases in 2025, so even a small share of outpatient infusion use can matter. For Enveric Biosciences, Inc., that widens access without changing the core product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEV102 dermatology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEV102 fits a market development move because the cannabinoid cream stays the same, but Enveric Biosciences, Inc. would sell it through dermatology and skin-care channels instead of a new product line. That matters because U.S. dermatology offices handled millions of patient visits in 2025, giving a clear route to test topical adoption without changing the formulation. The main hurdle is channel trust: dermatologists want clean safety, efficacy, and irritation data before adding a new cream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, new buyers\u003c\/li\u003e\n\u003cli\u003eDermatology channel first\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEV104 osteoarthritis care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEV104’s move into osteoarthritis would be market development: the same asset, but sold into musculoskeletal care instead of Enveric Biosciences, Inc.’s cancer-led focus. Osteoarthritis affects about 528 million people worldwide, so even a niche launch could reach a far larger patient base than oncology-only use. It also opens a separate payer and prescriber set, which can widen adoption if the clinical data support pain and function gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e528 million global OA cases\u003c\/li\u003e\n\u003cli\u003eNew musculoskeletal prescribers\u003c\/li\u003e\n\u003cli\u003eBroader non-oncology demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnveric Expands Into New Care Settings Without Changing Core Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc. fits market development when the same assets move into new care settings, like palliative care, hospice, dermatology, and musculoskeletal use. That expands buyers without changing the core products.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospice\u003c\/td\u003e\n\u003ctd\u003e1.7M U.S. beneficiaries, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer\u003c\/td\u003e\n\u003ctd\u003e2.0M new U.S. cases, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOA\u003c\/td\u003e\n\u003ctd\u003e528M global cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eEnveric Biosciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. It maps Enveric Biosciences’ growth options across market penetration, product development, market development, and diversification, highlighting near-term risks and actionable opportunities. Full editable version is available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVM-101 new asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVM-101 adds one new development program to Enveric Biosciences, Inc.'s cancer-related distress pipeline, so this is classic product development: new asset, same oncology-supportive-care market.\u003c\/p\u003e\n\u003cp\u003eIt broadens the company’s offer without changing the core customer need, which can help deepen relevance in a market where cancer burden remains high, with about 20 million new cases each year worldwide.\u003c\/p\u003e\n\u003cp\u003eFor Enveric Biosciences, Inc., the move expands the product set inside its existing therapeutic focus and can improve pipeline depth if the asset advances through early development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVM-201 new asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVM-201 is a second pipeline candidate in Enveric Biosciences, Inc.’s cancer-related distress area, so it fits Ansoff’s product development move: new product, same patient need. This deepens the Company Name's oncology-focused offer and gives it a broader shot at a niche market tied to distress care in cancer patients. The move matters because product development usually aims to lift share in an existing market without changing the core customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEV101 combination therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEV101 is a product-development move for Enveric Biosciences, Inc. that pairs cannabinoids with chemotherapy, creating a new cancer-care option inside its existing focus. In Ansoff terms, it is product development: a new therapy concept for a current market. The NCI said cancer caused about 1,958,310 new U.S. cases in 2023, so even a niche add-on can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEV102 topical cream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEV102 is Enveric Biosciences, Inc.’s topical cannabinoid cream for skin use, so it fits Product Development by adding a new formulation to the same cannabinoid platform. The move broadens the portfolio without changing the core market, and it targets a large dermocosmetic space where topical products make up a major share of consumer use, which can support faster testing and lower launch risk than a full new-market push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew cream, same cannabinoid platform\u003c\/li\u003e\n\u003cli\u003eExpands portfolio depth\u003c\/li\u003e\n\u003cli\u003eTargets topical skin use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEV104 and EVM-301 pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEV104 and EVM-301 add two named development programs to Enveric Biosciences, Inc.'s pipeline, which is clear product development under the Ansoff Matrix. That deepens the Company Name's portfolio across its chosen science base and lowers reliance on any single asset.\u003c\/p\u003e\n\u003cp\u003eIn portfolio terms, the move is not market expansion; it is a product development play that builds more shots on goal from the same core platform. The latest public filings do not give a new 2026 revenue figure for these candidates, so the main signal is pipeline breadth, not near-term sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo new programs broaden the pipeline.\u003c\/li\u003e\n\u003cli\u003eMore depth across the same science base.\u003c\/li\u003e\n\u003cli\u003eProduct development, not market expansion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnveric Expands Its Oncology Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc.'s EVM-101, EVM-201, EV101, EV102, EV104, and EVM-301 are product development plays: new assets and formulations inside the same oncology and cannabinoid focus.\u003c\/p\u003e\n\u003cp\u003eThat fits Ansoff because the Company Name is adding pipeline depth, not chasing a new market. The NCI counted 1,958,310 new U.S. cancer cases in 2023, so even niche distress-care adds can matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eType\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVM-101, EVM-201, EV101, EV102, EV104, EVM-301\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. new cancer cases, 2023\u003c\/td\u003e\n\u003ctd\u003e1,958,310\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEV104 osteoarthritis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEV104 is a diversification move for Enveric Biosciences, Inc. because it targets osteoarthritis, not the Company Name’s core cancer-care focus. That adds a new product in a new therapeutic market and pushes the Company Name into musculoskeletal disease. Osteoarthritis affects about 595 million people worldwide, so the addressable market is large.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVM-301 mental health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVM-301's mental health program is diversification in Enveric Biosciences, Inc.'s Ansoff Matrix because it pairs a new product with a new market. It moves Enveric Biosciences, Inc. beyond its oncology-linked pipeline and into psychiatry-focused care, where demand stays high and treatment gaps remain wide. That shift can widen the addressable market, but it also raises development risk and capital needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEV102 skin application\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEV102 is a cannabinoid cream for topical skin use, so Enveric Biosciences, Inc. is moving beyond cancer care into a separate dermatology path. That makes this Ansoff move diversification, because the clinical use and buyer set change, not just the delivery method. Topicals also fit a large skin-care market, which can broaden future pipeline value if EV102 shows clean safety and efficacy data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-oncology indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc. is using diversification in its Ansoff Matrix by pushing into 3 non-oncology lanes: osteoarthritis, mental health, and topical skin use. That cuts dependence on one therapeutic area and opens new shots at growth with new candidates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 non-oncology pipeline themes\u003c\/li\u003e\n\u003cli\u003eNew candidates, new markets\u003c\/li\u003e\n\u003cli\u003eLower single-area risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a small biotech, this matters because one program setback can hit value hard; spreading across 3 uses can smooth that risk while widening the addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-indication platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc. is using one cannabinoid-focused platform to move into 4 adjacent markets: cancer care, osteoarthritis, mental health, and skin use. That is classic diversification in the Ansoff Matrix because the same core science is being repurposed for new therapeutic uses. The result is a wider therapeutic footprint with more than 1 path to future value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 target markets\u003c\/li\u003e\n\u003cli\u003eOne shared platform\u003c\/li\u003e\n\u003cli\u003eNew uses, not one market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis setup lowers dependence on any single indication and can spread R\u0026amp;D risk across several programs. For Enveric Biosciences, Inc., the diversification story is not about more products yet; it is about one platform opening multiple clinical and commercial lanes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnveric’s New-Market Push Targets Massive Health Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnveric Biosciences, Inc. uses diversification by moving one cannabinoid platform into new therapeutic markets: osteoarthritis, psychiatry, and dermatology. That is a new product, new market play in Ansoff terms. The biggest signal is EV104, since osteoarthritis affects about 595 million people worldwide.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV104\u003c\/td\u003e\n\u003ctd\u003eOsteoarthritis\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVM-301\u003c\/td\u003e\n\u003ctd\u003eMental health\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV102\u003c\/td\u003e\n\u003ctd\u003eDermatology\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234333565193,"sku":"envb-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/envb-ansoff-matrix.webp?v=1785717843","url":"https:\/\/dcfanalyst.com\/products\/envb-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}